Larimar Therapeutics (LRMR) Non Operating Income (2013 - 2026)
Larimar Therapeutics' (LRMR) quarterly Non Operating Income came in at $1.5 million in Q4 2025, down 38.44% YoY from $2.5 million in Q4 2024, and down 14.94% on a QoQ basis from $1.8 million in Q3 2025.
Larimar Therapeutics (LRMR) Non Operating Income (2013 - 2026) Analysis & Trends
Larimar Therapeutics (LRMR) has 13 years of Non Operating Income data on file, last reported at $1.5 million in Q4 2025.
- Quarterly Non Operating Income fell 38.44% year-over-year to $1.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $6.8 million (down 33.66% YoY) and the FY2025 annual result came in at $6.8 million, down 33.66% from the prior year.
- Non Operating Income fell to $1.5 million in Q4 2025, from $1.8 million in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $3.0 million in Q2 2024 to a low of -$75000.0 in Q3 2021.
- A 5-year average of $1.1 million and a median of $1.2 million in 2023 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2022 — Non Operating Income slumped 411.11% — and 2023, when it soared 6170.0%.
- Tracing LRMR's Non Operating Income over 5 years: stood at -$48000.0 in 2021, then soared by 2212.5% to $1.0 million in 2022, then rose by 15.29% to $1.2 million in 2023, then soared by 111.21% to $2.5 million in 2024, then sank by 38.44% to $1.5 million in 2025.
- The last three Non Operating Income figures came in at $1.5 million (Q4 2025), $1.8 million (Q3 2025), and $1.6 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Larimar Therapeutics | 452.93 Mn | 296.66 Mn | - | 1.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.57 Mn |
| Dec 31, 2025 | 1.52 Mn |
| Sep 30, 2025 | 1.79 Mn |
| Jun 30, 2025 | 1.61 Mn |
| Mar 31, 2025 | 1.91 Mn |
| Dec 31, 2024 | 2.47 Mn |
| Sep 30, 2024 | 2.77 Mn |
| Jun 30, 2024 | 2.97 Mn |
| Mar 31, 2024 | 2.08 Mn |
| Dec 31, 2023 | 1.17 Mn |
| Sep 30, 2023 | 1.28 Mn |
| Jun 30, 2023 | 1.25 Mn |
| Mar 31, 2023 | 1.11 Mn |
| Dec 31, 2022 | 1.01 Mn |
| Sep 30, 2022 | 193,000.00 |
| Jun 30, 2022 | 20,000.00 |
| Mar 31, 2022 | -56,000.00 |
| Dec 31, 2021 | -48,000.00 |
| Sep 30, 2021 | -75,000.00 |
| Jun 30, 2021 | -66,000.00 |